Analystreport

CytomX Therapeutics (CTMX) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $12.00 price target on the stock, up from $7.00.

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com